Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Sep 26:14:1493854.
doi: 10.3389/fonc.2024.1493854. eCollection 2024.

Editorial: Bladder preservation options for bladder cancer

Nancy B Davis  1 , Deepak Kilari  2 , Elizabeth R Kessler  3 , Woodson W Smelser  4
Affiliations
Editorial

Editorial: Bladder preservation options for bladder cancer

Nancy B Davis et al. Front Oncol. .
No abstract available

Keywords: bladder cancer; bladder preservation; bladder sparing; chemoradiation; trimodality therapy.

PubMed Disclaimer

Conflict of interest statement

Author ND is as an employee of Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., and may hold stock and/or options in Merck & Co.,Inc., Rahway, NJ,USA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Bladder preservation options for bladder cancer

References

    1. Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. . Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. (2024) 390:875–88. doi: 10.1056/NEJMoa2312117 - DOI - PubMed
    1. van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. . Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. (2023) 389:1778–89. doi: 10.1056/NEJMoa2309863 - DOI - PubMed
    1. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. . A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. (2011) 12:211–4. doi: 10.1016/S1470-2045(10)70275-8 - DOI - PubMed
    1. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. . Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. (2021) 384:2102–14. doi: 10.1056/NEJMoa2034442 - DOI - PMC - PubMed
    1. Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim SP, et al. . Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol: Semin Orig Investigations. (2022) 40:272.e1–9. doi: 10.1016/j.urolonc.2021.12.015 - DOI - PubMed

Publication types

LinkOut - more resources